HUP0202648A2 - Imidazolilszármazékok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk - Google Patents

Imidazolilszármazékok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk

Info

Publication number
HUP0202648A2
HUP0202648A2 HU0202648A HUP0202648A HUP0202648A2 HU P0202648 A2 HUP0202648 A2 HU P0202648A2 HU 0202648 A HU0202648 A HU 0202648A HU P0202648 A HUP0202648 A HU P0202648A HU P0202648 A2 HUP0202648 A2 HU P0202648A2
Authority
HU
Hungary
Prior art keywords
alkyl
group
compounds
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU0202648A
Other languages
English (en)
Inventor
Marie-Odile Galcera
Thomas D. Gordon
Christophe Philippe Moinet
Barry Morgan
Lydie Francine Poitout
Christophe Alain Thurieau
Original Assignee
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. filed Critical Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S.
Publication of HUP0202648A2 publication Critical patent/HUP0202648A2/hu
Publication of HUP0202648A3 publication Critical patent/HUP0202648A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A találmány (I) általános képletű vegyületekre, azok racém ésdiasztereomer elegyeire és optikai izomerjeire, továbbá azokgyógyászatilag elfogadható sóira és elővegyületeire vonatkozik - aképletben a szubsztituensek főbb jelentései: - - - - - jelentése adottesetben jelen levő kötés; R1 jelentése H, -(CH2)m-C(O)-(CH2)m-Z1, -(CH2)m-Z1 vagy -(CH2)m-O-Z1 általános képletű csoport; Z1 jelentéseadott esetben szubsztituált 1-12 szénatomos alkilcsoport, fenilcsoportvagy naftilcsoport; R2 jelentése hidrogénatom vagy 1-6 szénatomosalkilcsoport; R3 jelentése -(CH2)m-E-(CH2)m-Z2 általános képletű csoport, ahol Ejelentése O, S vagy egy kötés; Z2 jelentése H, 1-12 szénatomosalkilcsoport vagy aminocsoport; R4 jelentése H vagy -(CH2)m-A1általános képletű csoport, ahol A1 jelentése X2 általános képletűcsoport, ahol X2 jelentése adott esetben szubsztituált 1-12 szénatomosalkilcsoport; R5 jelentése 1-12 szénatomos alkilcsoport; és R6jelentése H vagy 1-6 szénatomos alkilcsoport; és m értéke 0-6. Atalálmány szerinti vegyületek szomatosztatin-receptorok agonistáikéntvagy antagonistáiként használhatók fel. A találmány kiterjed avegyületeket tartalmazó gyógyászati készítményekre is. Ó
HU0202648A 1998-06-12 1999-06-08 Imidazolyl derivatives, pharmaceutical compositions containing them and their use HUP0202648A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9643198A 1998-06-12 1998-06-12
US8908798P 1998-06-12 1998-06-12
PCT/US1999/012760 WO1999064401A2 (en) 1998-06-12 1999-06-08 Imidazolyl derivatives and their use as somatostatin receptor ligands

Publications (2)

Publication Number Publication Date
HUP0202648A2 true HUP0202648A2 (hu) 2002-12-28
HUP0202648A3 HUP0202648A3 (en) 2003-02-28

Family

ID=26780237

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202648A HUP0202648A3 (en) 1998-06-12 1999-06-08 Imidazolyl derivatives, pharmaceutical compositions containing them and their use

Country Status (21)

Country Link
US (3) US6852725B1 (hu)
EP (1) EP1086086B1 (hu)
JP (1) JP2003523921A (hu)
CN (1) CN1319094A (hu)
AR (1) AR018671A1 (hu)
AT (1) ATE279396T1 (hu)
AU (1) AU746963B2 (hu)
CA (1) CA2334945A1 (hu)
CZ (1) CZ20004568A3 (hu)
DE (1) DE69921124T2 (hu)
DK (1) DK1086086T3 (hu)
ES (1) ES2229718T3 (hu)
HK (1) HK1031873A1 (hu)
HU (1) HUP0202648A3 (hu)
IL (1) IL139835A (hu)
NO (2) NO20006267L (hu)
PL (1) PL347139A1 (hu)
PT (1) PT1086086E (hu)
RU (1) RU2263111C2 (hu)
TW (1) TWI245758B (hu)
WO (1) WO1999064401A2 (hu)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852725B1 (en) * 1998-06-12 2005-02-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S. A. S. Imidazolyl derivatives
US6518292B1 (en) * 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
US6525203B1 (en) 1999-03-12 2003-02-25 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
KR20010112408A (ko) * 1999-04-07 2001-12-20 모리타 다카카즈 Ｎ-치환되고-Ｎ'-치환된 우레아 유도체 및 ＴＮＦ-α 생성억제제로서의 그의 용도
FR2796945B1 (fr) 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
US6696418B1 (en) 1999-09-01 2004-02-24 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
FR2812546B1 (fr) * 2000-08-01 2008-11-21 Sod Conseils Rech Applic Derives d'heterocycles a 5 chainons, leur preparation et leur application a titre de medicaments
TWI292316B (en) * 1999-10-11 2008-01-11 Sod Conseils Rech Applic Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof
PL354759A1 (en) 1999-11-04 2004-02-23 Ortho-Mcneil Pharmaceutical, Inc. Nonpeptide substituted benzothiazepines as vasopressin antagonists
US6495589B2 (en) 2000-04-28 2002-12-17 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
US6372795B1 (en) * 2000-06-30 2002-04-16 Unilever Home And Personal Care Usa, A Division Of Conopco, Inc. Cosmetic compositions containing substituted amide derivatives
AU7909801A (en) 2000-08-01 2002-02-13 Sod Conseils Rech Applic Imidazolyl derivatives
US6653478B2 (en) 2000-10-27 2003-11-25 Ortho-Mcneil Pharmaceutical, Inc. Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators
US6720330B2 (en) 2000-11-17 2004-04-13 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
WO2003000196A2 (en) * 2001-06-25 2003-01-03 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof
EP1465880B1 (fr) * 2001-11-28 2009-08-05 Ipsen Pharma Derives de 5-sulfanyl-4h-1,2,4-triazoles pour traiter les désordres associés à la somatostatine
FR2832710B1 (fr) * 2001-11-28 2004-09-03 Sod Conseils Rech Applic Derives de 5-sulfanyl-4h-1,2,4-triazoles et leur utilisation en tant que medicaments
US20060241132A1 (en) * 2002-03-22 2006-10-26 Toray Industries, Inc. A Corporation Of Japan Spiro derivatives and adhesion molecule inhibitors comprising the same as active ingredient
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
FI20031454A0 (fi) * 2003-10-06 2003-10-06 Juvantia Pharma Ltd Oy Selektiivisiä somatostatiinireseptori 1 ja/tai 4 -agonisteja ja -antagonisteja
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7863294B2 (en) 2004-12-10 2011-01-04 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Heterocycle derivatives as histone deacetylase (HDAC) inhibitors
WO2006063465A1 (en) 2004-12-15 2006-06-22 Diamedica Inc. Treatment of insulin resistance by modulating somatostatin using somatostatin receptor antagonists
AU2006222243B2 (en) 2005-03-09 2012-04-05 F. Hoffmann La-Roche Ag Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives as antidiabetic compounds
MY147188A (en) * 2005-08-09 2012-11-14 Novartis Ag Substituted imidazole compounds as ksp inhibitors
GB0522130D0 (en) 2005-10-31 2005-12-07 Angeletti P Ist Richerche Bio Therapeutic compounds
US7626039B2 (en) 2005-12-14 2009-12-01 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors
CN101341129B (zh) * 2005-12-14 2011-12-14 布里斯托尔-迈尔斯斯奎布公司 作为因子xia抑制剂的芳基丙酰胺，芳基丙烯酰胺，芳基丙炔酰胺，或芳基甲基脲类似物
DE102007032349A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
KR101792837B1 (ko) 2009-04-16 2017-11-02 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ 키나아제 억제제로서 사용을 위한 이미다조피라진
JO3156B1 (ar) 2009-07-09 2017-09-20 Novartis Ag ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا
US8987310B2 (en) 2009-10-30 2015-03-24 Merck Sharp & Dohme Corp. Heterocycle amide T-type calcium channel antagonists
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
WO2013005798A1 (ja) * 2011-07-06 2013-01-10 持田製薬株式会社 新規含窒素複素環誘導体
US10858314B2 (en) 2015-05-27 2020-12-08 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
CA3059327A1 (en) 2017-04-24 2018-11-01 Novartis Ag Therapeutic regimen of 2-amino-l-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8h)-yl)ethanone and combinations thereof
JP2020523362A (ja) * 2017-06-14 2020-08-06 ヨーロピアン モレキュラー バイオロジー ラボラトリーＥｕｒｏｐｅａｎ Ｍｏｌｅｃｕｌａｒ Ｂｉｏｌｏｇｙ Ｌａｂｏｒａｔｏｒｙ 治療への使用のための二環式複素芳香族尿素またはカルバメート化合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US728695A (en) * 1902-07-19 1903-05-19 James Fitzgerald Combined stool and quilting-frame.
FR2132632A1 (en) * 1971-04-07 1972-11-24 Berlin Chemie Veb Prepn of 2-aminomethyl imidazole derivs - hypotensives mao inhibitors anticonvulsant s, antiphlogistics, choleretics and ant
GB8416295D0 (en) * 1984-06-27 1984-08-01 Wellcome Found Bicyclic compounds
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
JP2621292B2 (ja) * 1988-02-05 1997-06-18 武田薬品工業株式会社 抗菌化合物
EP0655055B1 (en) * 1992-08-13 2000-11-29 Warner-Lambert Company Tachykinin antagonists
WO1995008550A1 (en) * 1993-09-24 1995-03-30 Abbott Laboratories Endothelin antagonists
US5733882A (en) * 1994-01-17 1998-03-31 Smithkline Beecham Corporation Retroviral protease inhibitors
NZ290008A (en) * 1994-06-29 1998-08-26 Smithkline Beecham Corp Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle
WO1996011927A1 (en) 1994-10-12 1996-04-25 Abbott Laboratories Endothelin antagonists
CN1088062C (zh) * 1994-11-23 2002-07-24 纽罗根公司 某些4－氨基甲基－2－取代的咪唑衍生物2－氨基甲基－4－取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体
AU1354097A (en) 1995-12-29 1997-07-28 Smithkline Beecham Corporation Vitronectin receptor antagonists
US6673927B2 (en) * 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
WO1997043278A1 (en) * 1996-05-14 1997-11-20 Novo Nordisk A/S Somatostatin agonists and antagonists
EP0914322A1 (en) 1996-05-27 1999-05-12 Fujisawa Pharmaceutical Co., Ltd. New indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production
EP0946587A2 (en) * 1996-12-16 1999-10-06 Fujisawa Pharmaceutical Co., Ltd. New amide compounds
ES2216290T3 (es) * 1997-05-13 2004-10-16 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Somatostatina y agonistas de la somatostatina para el tratamiento de insensibilidad a la insulina y de sindrome x.
WO1998051330A1 (en) * 1997-05-13 1998-11-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Method and compositions for treating hyperlipidemia and other conditions
US6852725B1 (en) 1998-06-12 2005-02-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S. A. S. Imidazolyl derivatives
AU745493B2 (en) 1998-06-16 2002-03-21 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Cyclic somatostatin analogs
WO2000000477A1 (en) 1998-06-30 2000-01-06 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases

Also Published As

Publication number Publication date
AU746963B2 (en) 2002-05-09
US20040176379A1 (en) 2004-09-09
EP1086086B1 (en) 2004-10-13
NO20006267L (no) 2001-02-07
US20070299073A1 (en) 2007-12-27
HK1031873A1 (en) 2001-06-29
HUP0202648A3 (en) 2003-02-28
CN1319094A (zh) 2001-10-24
WO1999064401A2 (en) 1999-12-16
WO1999064401A3 (en) 2003-04-17
EP1086086A1 (en) 2001-03-28
DE69921124D1 (de) 2004-11-18
CA2334945A1 (en) 1999-12-16
IL139835A (en) 2005-11-20
ES2229718T3 (es) 2005-04-16
PL347139A1 (en) 2002-03-25
ATE279396T1 (de) 2004-10-15
TWI245758B (en) 2005-12-21
PT1086086E (pt) 2005-02-28
US6852725B1 (en) 2005-02-08
DE69921124T2 (de) 2005-11-10
AU4425799A (en) 1999-12-30
US7238695B2 (en) 2007-07-03
NO20006267D0 (no) 2000-12-11
DK1086086T3 (da) 2005-01-24
RU2263111C2 (ru) 2005-10-27
NO20060154L (no) 1999-12-13
AR018671A1 (es) 2001-11-28
IL139835A0 (en) 2002-02-10
CZ20004568A3 (cs) 2001-11-14
JP2003523921A (ja) 2003-08-12

Similar Documents

Publication Publication Date Title
HUP0202648A2 (hu) Imidazolilszármazékok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0203700A2 (hu) N-szubsztituált cianopirrolidinek és cukorbetegség-ellenes szerként való alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények
HUP0400636A2 (hu) Azetidinszármazékokat tartalmazó gyógyszerkészítmények, új azetidinszármazékok és előállításuk
HUP0102453A2 (hu) Adenozinszármazékok, alkalmazásuk és e vegyületeket tartalmazó gyógyászati készítmények
HUP0100615A2 (hu) Szubsztituált 2-(2,6-dioxo-3-fluoro-piperidin-3-il)-izoindolinok és ezek alkalmazása TNFalfa-szint csökkentésére
UY27384A1 (es) Analogos de prostaglandina
BG108420A (en) New indole derivatives with 5-ht6 receptor affinity
UA72917C2 (en) Cyclic carbamates derivatives, pharmaceutical composition containing said derivatives of cyclic carbamates and active ingredients as modulators of the progesterone receptor
HUP0103404A2 (hu) Oxazolidinonszármazékok, eljárás előállításukra, és az azokat tartalmazó gyógyászati készítmények
HUP0402235A2 (hu) 4,4-Difluor-1,2,3,4-tetrahidro-5H-1-benzazepin-származékok és ezek sói és ezeket tartalmazó gyógyszerkészítmények
HUP0401235A2 (hu) 5-HT6 receptor affinitással rendelkező arilszulfonil-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
HUP0100024A2 (hu) Alzheimer-kór kezelésére szolgáló hatóanyagként karvedilolszármazékokat tartalmazó gyógyszerkészítmények
HUP0302193A2 (hu) 1,4-Diazabiciklo[3.2.2]nonán-benzoxazol,-benzotiazol és -benzimidazol-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
HUP0200121A2 (hu) Kalcilitikus vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0203622A2 (hu) Biciklusos vazopresszin agonisták és ezeket tartalmazó gyógyszerkészítmények
HUP0203275A2 (hu) 1-(Gyűrűs amino)-alkilciklohexán-származékok, ezeket tartalmazó görcsoldó hatású gyógyszerkészítmények, valamint ezek alkalmazása
AR023111A1 (es) Derivados de sulfonamida utiles como antagonistas del receptor 5-ht7, un procedimiento para su preparacion y composicion farmaceutica que los comprenden
HUP0002929A2 (hu) Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények
IL109744A0 (en) 3-(indol-3-yl) propenoic acid derivatives and pharmaceutical compositions thereof
HUP9901137A2 (hu) N-szulfonil- és N-szulfinil-aminosav-származékok, előállításuk, a vegyületeket hatóanyagként tartalmazó mikrobicid készítmények és alkalmazásuk
ATE502034T1 (de) Thiazolidindionderivate und diese enthaltende pharmazeutische zusammensetzung
HUP0002715A2 (hu) Benzotiofénszármazékok alkalmazása trombocitaszám csökkentésére szolgáló gyógyszerkészítmények előállítására
HUP0401076A2 (hu) Alfa-2B-andrenoceptor antagonista vegyületek és alkalmazásuk gyógyszerkészítmények előállítására
BG106079A (en) Cyclocarbamate derivatives as progesterone receptor modulators
HUP0001311A2 (hu) Dopamin agonista hatású 5-amino-alkoxi-1,4-dihidro-kinoxalin-2,3-dion-származékok és a vegyületeket tartalmazó gyógyszerkészítmények